Ionis Pharmaceuticals Inc(IONS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 10 at 7:30 PM ET (Korea 9/11 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.47 | Insider Own | 1.96% | Shs Outstand | 165.6M | Perf Week | -9.26% |
| Market Cap | 9.25B | Forward P/E | - | EPS next Y | 46.14% | Insider Trans | -19.88% | Shs Float | 162.9M | Perf Month | 0.42% |
| Enterprise Value | 9.38B | PEG | - | EPS next Q | -1.21 | Inst Own | 107.82% | Short Float | 12.83% | Perf Quarter | -24.1% |
| Income | -0.56B | P/S | 10.58 | EPS this Y | -53.33% | Inst Trans | 4.35% | Short Ratio | 6.63 | Perf Half Y | -25.59% |
| Sales | 0.87B | P/B | 20.96 | EPS next 5Y | - | ROA | -18.89% | Short Interest | 20.91M | Perf YTD | -29.65% |
| Book/sh | 2.65 | P/C | 4.5 | EPS past 3/5Y | -7.82% 5.62% | ROE | -105.42% | 52W High | -35.84% ($86.74) | Perf Year | -13.05% |
| Cash/sh | 12.36 | P/FCF | - | Sales past 3/5Y | 17.12% 5.29% | ROIC | -21.59% | 52W Low | 11.29% ($50.01) | Perf 3Y | 35.04% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -98.12% | Gross Margin | 95.66% | Volatility(W/M) | 4.58% 3.35% | Perf 5Y | 54.2% |
| Dividend TTM | - | EV/Sales | 10.74 | Sales Y/Y TTM | -7.49% | Oper. Margin | -68.09% | ATR (14) | 2.16 | Perf 10Y | 91.83% |
| Dividend Ex-Date | - | Quick Ratio | 7.73 | EPS Q/Q | -202.29% | Profit Margin | -64.64% | RSI (14) | 38.81 | Recom | 1.56 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.89 | Sales Q/Q | -40.73% | SMA20 | -6.41% ($59.46) | Beta | 0.36 | Target Price | $84.24 |
| Payout | - | Debt/Eq | 4.98 | Earnings | 2026/7/29 | SMA50 | -6.91% ($59.78) | Rel Volume | 0.93 | Prev Close | $56.02 |
| Employees | 1402 | LT Debt/Eq | 4.95 | EPS/Sales Surpr. | 36.63% 41.73% | SMA200 | -23.93% ($73.16) | Avg Volume(3M) | 3.15M | Price | $55.65 |
| IPO | 1991/5/17 | Option/Short | Yes/Yes | Trades | 22258 | Volume | 2,938,267 | Change | -0.66% |
Company
IONS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
This U.S. biopharmaceutical company is a leading player in antisense drug development, creating treatments for rare and chronic diseases based on antisense technology that regulates protein production at the genetic level. The company is currently transitioning toward the commercialization of its own drug products.
Over the past 1 year, on the lower side
36% below its 1-year high.
IONS has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -53.3% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +35.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 107.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
MEDX 0.05%
PBE 0.02%
PTH 0.02%
FFOX 0.02%
QMOM 0.02%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
JEPI 45.5B
JEPQ 42.4B
BOXX 14.8B
QQQI 14.3B
SPYI 11.7BIt ranks #4 in the industry
Based on market cap of $9B.
IONS $9B PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is IONS?
IONS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IONS?
The market cap of IONS is approximately $9.2B, ranking 990 within its sector.
What is the 52-week high and low for IONS?
IONS has recorded a 52-week high of $86.74 and a low of $50.01.
